Mucocutaneous manifestations of Epstein-Barr virus infection

American Journal of Clinical Dermatology

Volumn 9, Issue 5, 2008, Pages 295-305

  Mendoza, Natalia ^a,b   Diamantis, Melissa ^c   Arora, Anita ^d   Bartlett, Brenda ^a   Gewirtzman, Aron ^a   Tremaine, Anne Marie ^a   Tyring, Stephen ^d  

^a CENTER FOR CLINICAL STUDIES   (United States)

^b UNIVERSIDAD EL BOSQUE   (Colombia)

^c UNIVERSITY OF TEXAS   (United States)

^d University of Texas Health Science Center at Houston   (United States)

Author keywords

Epstein Barr virus infections, general

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIINFECTIVE AGENT; CETIRIZINE; CORTICOSTEROID; DESCICLOVIR; EBASTINE; EPSTEIN BARR VIRUS VACCINE; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; HYDROXYUREA; IMMUNOGLOBULIN; LORATADINE; PLACEBO; PODOPHYLLIN; PREDNISONE; RETINOID; RITUXIMAB; VALACICLOVIR;

B LYMPHOCYTE; BURKITT LYMPHOMA; CELLULAR IMMUNITY; CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOTHERAPY; DISEASE COURSE; EPSTEIN BARR VIRUS; EXCISION; HEMOPHAGOCYTIC SYNDROME; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNITY; HYDROA VACCINIFORME; HYPERSENSITIVITY; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOCOMPROMISED PATIENT; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFECTIOUS MONONUCLEOSIS; INSECT BITE; KIKUCHI DISEASE; LEUKOPLAKIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MOSQUITO; NASOPHARYNX CARCINOMA; PAPULAR ACRODERMATITIS; PATHOPHYSIOLOGY; PLASMABLASTIC LYMPHOMA; PRIMARY INFECTION; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN MANIFESTATION; SOLID TUMOR; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MUCOUS MEMBRANE; SKIN DISEASES, INFECTIOUS;

EID: 50049133202     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200809050-00003     Document Type: Review

References (95)

1. Brown RS, Campbell C, Lishman SC, et al. Plasmablastic lymphoma: a new subcategory of human immunodeficiency virus-related non-Hodgkin's lymphoma. Clin Oncol (R Coll Radiol) 1998; 10 (5): 327-9
2. Puchhammer-Stockl E, Gorzer I. Cytomegalovirus and Epstein-Barr virus subtypes: the search for clinical significance. J Clin Virol 2006; 36 (4): 239-48
3. Klein E, Kis LL, Klein G. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 2007; 26 (9): 1297-305
4. Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 1994; 77 (6): 791-3
5. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 15: 702-3
6. Henle G, Henle W, Diehl V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci U S A 1968; 59 (1): 94-101
7. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 2006; 107 (3): 862-9
8. National Center for Infectious Diseases. Epstein-Barr virus and infectious mononucleosis [online]. Available from URL: http://www.cdc.gov/ ncidod/diseases/ebv.htm [Accessed 2008 Jun 4]
9. Bennett NJ, Domachowske J, Winnie GB, et al. Mononucleosis and Epstein-Barr virus infection, last updated 2007 Jul 9 [online]. Available from URL: http://www.emedicine.com/ped/topic705.htm [Accessed 2008 Jun 4]
10. Henle W, Henle GE, Horwitz CA. Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Human Pathol 1974; 5 (5): 551-65
11. Lanier A, Bender T, Talbot M, et al. Nasopharyngeal carcinoma in Alaskan Eskimos Indians, and Aleuts: a review of cases and study of Epstein-Barr virus, HLA, and environmental risk factors. Cancer 1980; 46 (9): 2100-6
12. Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Physician 2004; 70 (7): 1279-87
13. Iwatsuki K, Xu Z, Ohtsuka M, et al. Cutaneous lymphoproliferative disorders associated with Epstein-Barr virus infection: a clinical overview. J Dermatol Sci 2000; 22 (3): 181-95
14. Cheng CC, Chang LY, Shao PL, et al. Clinical manifestations and quantitative analysis of virus load in Taiwanese children with Epstein-Barr virus-associated infectious mononucleosis. J Microbiol Immunol Infect 2007; 40 (3): 216-21
15. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Ann Rev Immunol 1997; 15: 405-31
16. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343 (7): 481-92
17. Amon W, Farrell PJ. Reactivation of Epstein-Barr virus from latency. Rev Med Virol 2005; 15 (3): 149-56
18. Babcock GJ, Decker LL, Volk M, et al. EBV persistence in memory B cells in vivo. Immunity 1998; 9 (3): 395-404
19. Brooks LA, Lear AL, Young LS, et al. Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol 1993; 67 (6): 3182-90
20. Iwatsuki K, Satoh M, Yamamoto T, et al. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol 2006; 142 (5): 587-95
21. Iwatsuki K, Ohtsuka M, Harada H, et al. Clinicopathologic manifestations of Epstein-Barr virus-associated cutaneous lymphoproliferative disorders. Arch Dermatol 1997; 133 (9): 1081-6
22. Iwatsuki K, Yamamoto T, Tsuji K, et al. A spectrum of clinical manifestations caused by host immune responses against Epstein-Barr virus infections. Acta Med Okayama 2004; 58 (4): 169-80
23. Gershburg E, Pagano JS. Epstein-Barr virus infections: prospects for treatment. J Antimicrob Chemother 2005; 56 (2): 277-81
24. Peter J, Ray CG. Infectious mononucleosis. Pediatr Rev 1998; 19 (8): 276-9
25. Yoda K, Sata T, Kurata T, et al. Oropharyngotonsillitis associated with nonprimary Epstein-Barr virus infection. Arch Otolaryngol Head Neck Surg 2000; 126 (2): 185-93
26. McCarthy JT, Hoagland RJ. Cutaneous manifestations of infectious mononucleosis. JAMA 1964; 187: 153-4
27. Rea TD, Russo JE, Katon W, et al. Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract 2001; 14 (4): 234-42
28. Walling DM, Hudnall SD, Yen-Moore A. Epstein-Barr virus. In: Tyring SK, editor. Mucocutaneous manifestations of viral diseases. New York: Marcel Dekker, 2002: 145-71
29. Barnes CJ, Alio AB, Cunningham BB, et al. Epstein-Barr virus-associated genital ulcers: an under-recognized disorder. Pediatr Dermatol 2007; 24 (2): 130-4
30. Sisson BA, Glick L. Genital ulceration as a presenting manifestation of infectious mononucleosis. J Pediatr Adolesc Gynecol 1998; 11 (4): 185-7
31. Halvorsen JA, Brevig T, Aas T, et al. Genital ulcers as initial manifestation of Epstein-Barr virus infection: two new cases and a review of the literature. Acta Derm Venereol 2006; 86 (5): 439-42
32. Caputo R, Gelmetti C, Ermacora E, et al. Gianotti-Crosti syndrome: a retrospective analysis of 308 cases. J Am Acad Dermatol 1992; 26 (2 Pt 1): 207-10
33. Brandt O, Abeck D, Gianotti R, et al. Gianotti-Crosti syndrome. J Am Acad Dermatol 2006; 54 (1): 136-45
34. Yen A, Fearneyhough P, Raimer SS, et al. EBV-associated Kikuchi's histiocytic necrotizing lymphadenitis with cutaneous manifestations. J Am Acad Dermatol 1997; 36 (2 Pt 2): 342-6
35. Seno A, Torigoe R, Shimoe K, et al. Kikuchi's disease (histiocytic necrotizing lymphadenitis) with cutaneous involvement. J Am Acad Dermatol 1994; 30 (3): 504-6
36. Iwatsuki K, Xu Z, Takata M, et al. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol 1999; 140 (4): 715-21
37. Gupta G, Man I, Kemmett D. Hydroa vacciniforme: a clinical and follow-up study of 17 cases. J Am Acad Dermatol 2000; 42 (2 Pt 1): 208-13
38. Asada H. Hypersensitivity to mosquito bites: a unique pathogenic mechanism linking Epstein-Barr virus infection, allergy and oncogenesis. J Dermatol Sci 2007; 45 (3): 153-60
39. Asada H, Miyagawa S, Sumikawa Y, et al. CD4+ T-lymphocyte-induced Epstein-Barr virus reactivation in a patient with severe hypersensitivity to mosquito bites and Epstein-Barr virus-infected NK cell lymphocytosis. Arch Dermatol 2003; 139 (12): 1601-7
40. Greenspan JS, Greenspan D, Lennette ET, et al. Replication of Epstein-Barr virus within the epithelial cells of oral 'hairy' leukoplakia, an AIDS-associated lesion. N Engl J Med 1985; 313 (25): 1564-71
41. Slots J, Saygun I, Sabeti M, et al. Epstein-Barr virus in oral diseases. J Periodontal Res 2006; 41 (4): 235-44
42. Ranganathan K, Reddy BV, Kumarasamy N, et al. Oral lesions and conditions associated with human immunodeficiency virus infection in 300 South Indian patients. Oral Dis 2000; 6 (3): 152-7
43. Kamiru HN, Naidoo S. Oral HIV lesions and oral health behaviour of HIV-positive patients attending the Queen Elizabeth II Hospital, Maseru, Lesotho. SADJ 2002; 57 (11): 479-82
44. Reznik DA. Oral manifestations of HIV disease. Top HIV Med 2005; 13 (5): 143-8
45. Itin PH. Oral hairy leukoplakia: 10 years on. Dermatology 1993; 187 (3): 159-63
46. Ficarra G, Gaglioti D, Di Pietro M, et al. Oral hairy leukoplakia: clinical aspects, histologic morphology and differential diagnosis. Head Neck 1991; 13 (6): 514-21
47. Migliorati CA, Jones AC, Baughman PA. Use of exfoliative cytology in the diagnosis of oral hairy leukoplakia. Oral Surg Oral Med Oral Pathol 1993; 76 (6): 704-10
48. Carbone A, Gaidano G, Gloghini A, et al. AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. Ann Otol Rhinol Laryngol 1999; 108 (1): 95-9
49. Flaitz CM, Nichols CM, Walling DM, et al. Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations. Oral Oncol 2002; 38 (1): 96-102
50. Tan HH, Goh CL. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am J Clin Dermatol 2006; 7 (1): 13-29
51. Dunphy CH, Gardner LJ, Grosso LE, et al. Flow cytometric immunophenotyping in posttransplant lymphoproliferative disorders. Am J Clin Pathol 2002; 117 (1): 24-8
52. Euvrard S, Noble CP, Kanitakis J, et al. Brief report: successive occurrence of T-cell and B-cell lymphomas after renal transplantation in a patient with multiple cutaneous squamous-cell carcinomas. N Engl J Med 1992; 327 (27): 1924-6
53. Salama S. Primary 'cutaneous' T-cell anaplastic large cell lymphoma, CD30+, neutrophil-rich variant with subcutaneous panniculitic lesions, in a post-renal transplant patient: report of unusual case and literature review. Am J Dermatopathol 2005; 27 (3): 217-23
54. Pascual J, Torrelo A, Teruel JL, et al. Cutaneous T cell lymphomas after renal transplantation. Transplantation 1992; 53 (5): 1143-5
55. Tomson CR, Graham S, Hutchinson RM, et al. Sezary cell lymphoma following cyclosporin immunosuppression for renal transplantation. Nephrol Dial Transplant 1991; 6 (11): 896-8
56. Takahashi S, Watanabe D, Miura K, et al. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder presenting with skin involvement after CD34-selected autologous peripheral blood stem cell transplantation. Eur J Dermatol 2007; 17 (3): 242-4
57. Pettey AA, Walsh JS. Cutaneous involvement with Burkitt-like lymphoma. Am J Dermatopathol 2007; 29 (2): 184-6
58. de-Thé G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 1978; 274 (5673): 756-61
59. Jacobson MA, Hutcheson AC, Hurray DH, et al. Cutaneous involvement by Burkitt lymphoma. J Am Acad Dermatol 2006; 54 (6): 1111-3
60. Rickinson A. Epstein-Barr virus. Virus Res 2002; 82 (1-2): 109-13
61. Bachmeyer C, Bazarbachi A, Rio B, et al. Specific cutaneous involvement indicating relapse of Burkitt's lymphoma [letter]. Am J Hematol 1997; 54 (2): 176
62. Weiss LM, Movahed LA, Warnke RA, et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. New Engl J Med 1989; 320 (8): 502-6
63. Landgren O, Caporaso NE. New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007; 21 (5): 825-40
64. Herbst H, Stein H, Niedobitek G. Epstein-Barr virus and CD30+ malignant lymphomas. Crit Rev Oncog 1993; 4 (2): 191-239
65. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997; 70 (4): 375-82
66. Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus: altered antibody pattern before diagnosis. New Engl J Med 1989; 320 (11): 689-95
67. Sioutos N, Kerl H, Murphy SB, et al. Primary cutaneous Hodgkin's disease: unique clinical, morphologic, and immunophenotypic findings. Am J Dermatopathol 1994; 16 (1): 2-8
68. Vasef MA, Kamel OW, Chen YY, et al. Detection of Epstein-Barr virus in multiple sites involved by Hodgkin's disease. Am J Pathol 1995; 147 (5): 1408-15
69. Zeng Y, Zhang LG, Li HY, et al. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer 1982; 29 (2): 139-41
70. Pathmanathan R, Prasad U, Chandrika G, et al. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx: variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 1995; 146 (6): 1355-67
71. Pathmanathan R, Prasad U, Sadler R, et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. New Engl J Med 1995; 333 (11): 693-8
72. Halprin J, Scott AL, Jacobson L, et al. Enzyme-linked immunosorbent assay of antibodies to Epstein-Barr virus nuclear and early antigens in patients with infectious mononucleosis and nasopharyngeal carcinoma. Ann Intern Med 1986; 104 (3): 331-7
73. Rogers R, Windust A, Gregory J. Evaluation of a novel dry latex preparation for demonstration of infectious mononucleosis heterophile antibody in comparison with three established tests. J Clin Microbiol 1999; 37 (1): 95-8
74. Luderer R, Kok M, Niesters HG, et al. Real-time Epstein-Barr virus PCR for the diagnosis of primary EBV infections and EBV reactivation. Mol Diagn 2005; 9 (4): 195-200
75. Pitetti RD, Laus S, Wadowsky RM. Clinical evaluation of a quantitative real time polymerase chain reaction assay for diagnosis of primary Epstein-Barr virus infection in children. Pediatr Infect Dis J 2003; 22 (8): 736-9
76. Brengel-Pesce K, Morand P, Schmuck A, et al. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. J Med Virol 2002; 66 (3): 360-9
77. Jackson JM. Emerging infections in dermatology. Semin Cutan Med Surg 2006; 25 (4): 201-6
78. Copur MS, Deshpande A, Mleczko K, et al. Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides. Croat Med J 2005; 46 (3): 458-62
79. Krause I, Wu R, Sherer Y, et al. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations: a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 2002; 12 (2): 133-9
80. Drago F, Ranieri E, Pastorino A, et al. Epstein-Barr virus-related primary cutaneous amyloidosis: successful treatment with acyclovir and interferon-alpha. Br J Dermatol 1996; 134 (1): 170-4
81. Zompi S, Tulliez M, Conti F, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. J Hepatol 2000; 32 (3): 521-7
82. Candy B, Hotopf M. Steroids for symptom control in infectious mononucleosis. Cochrane Database Syst Rev 2006; (3): CD004402
83. Tynell E, Aurelius E, Brandell A, et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. J Infect Dis 1996; 174 (2): 324-31
84. Tilly JJ, Drolet BA, Esterly NB. Lichenoid eruptions in children. J Am Acad Dermatol 2004; 51 (4): 606-24
85. Lenane P, Murphy GM. Sunscreens and the photodermatoses. J Dermatolog Treat 2001; 12 (1): 53-7
86. Reunala T, Brummer-Korvenkontio H, Petman L, et al. Effect of ebastine on mosquito bites. Acta Derm Venereol 1997; 77 (4): 315-6
87. Karppinen A, Kautiainen H, Reunala T, et al. Loratadine in the treatment of mosquito-bite-sensitive children. Allergy 2000; 55 (7): 668-71
88. Reunala T, Lappalainen P, Brummer-Korvenkontio H, et al. Cutaneous reactivity to mosquito bites: effect of cetirizine and development of anti-mosquito antibodies. Clin Exp Allergy 1991; 21 (5): 617-22
89. Greenspan D, De Souza YG, Conant MA, et al. Efficacy of desciclovir in the treatment of Epstein-Barr virus infection in oral hairy leukoplakia. J Acquir Immune Defic Syndr 1990; 3 (6): 571-8
90. Triantos D, Porter SR, Scully C, et al. Oral hairy leukoplakia: clinicopathologic features, pathogenesis, diagnosis, and clinical significance. Clin Infect Dis 1997; 25 (6): 1392-6
91. Pastore L, De Benedittis M, Petruzzi M, et al. Efficacy of famciclovir in the treatment of oral hairy leukoplakia. Br J Dermatol 2006; 154 (2): 378-9
92. Moura MD, Guimaraes TR, Fonseca LM, et al. A random clinical trial study to assess the efficiency of topical applications of podophyllin resin (25%) versus podophyllin resin (25%) together with acyclovir cream (5%) in the treatment of oral hairy leukoplakia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103 (1): 64-71
93. Fraga M, Forteza J. Diagnosis of Hodgkin's disease: an update on histopathological and immunophenotypical features. Histol Histopathol 2007; 22 (8): 923-35
94. Okebe JU, Lasserson TJ, Meremikwu MM, et al. Therapeutic interventions for Burkitt's lymphoma in children. Cochrane Database Syst Rev 2006; (4): CD005198
95. Moutschen M, Leonard P, Sokal EM, et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 2007; 25 (24): 4697-705